Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Primes For US Momentum But Seretide Generic Is Slow In UK

Executive Summary

Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.


Related Content

Can Glenmark-Celon’s Generic Seretide DPI Break Into Germany?
Can Glenmark-Celon’s Generic Seretide DPI Break Into Germany?
Cipla Sounds The Bugle On US Respiratory Ambition
Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress
Cipla Revs Up In US, Newer Markets To Cushion Against Volatility
Cipla Signals US Launch Momentum, Commodity-Like Price Cycle
Cipla, Sandoz Gearing For Seretide Challenge In Australia?
Christmas Cheer For Cipla’s Seretide Equivalent In The UK


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts